Why the study?
Are PAD3/PAD4 cross-reactive autoantibodies associated with increased radiographic damage and progression in patients with rheumatoid arthritis?
Are PAD3/PAD4 cross-reactive autoantibodies associated with increased radiographic damage and progression in patients with rheumatoid arthritis?
PAD3/PAD4 cross-reactive autoantibodies activate PAD4 by increasing calcium sensitivity, driving erosive outcomes in RA and identifying patients who may benefit from early aggressive treatment.
No takes yet. Share an insight, caveat, or question.
PAD3/PAD4 autoantibodies were associated with erosive RA; hypothesis-generating and should not yet change practice.
Darrah et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: